{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:54:41Z","timestamp":1793840081851,"version":"4.6.1"},"reference-count":100,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,2,5]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) has demonstrated durable clinical responses in patients with metastatic melanoma, substantiated by recent positive results of the first phase III trial on TIL therapy. Being a demanding and logistically complex treatment, extensive preclinical and clinical effort is required to optimize patient selection by identifying predictive biomarkers of response. This review aims to comprehensively summarize the current evidence regarding the potential impact of tumor-related factors (such as mutational burden, neoantigen load, immune infiltration, status of oncogenic driver genes, and epigenetic modifications), patient characteristics (including disease burden and location, baseline cytokines and lactate dehydrogenase serum levels, human leucocyte antigen haplotype, or prior exposure to immune checkpoint inhibitors and other anticancer therapies), phenotypic features of the transferred T cells (mainly the total cell count, CD8:CD4 ratio, ex vivo culture time, expression of exhaustion markers, costimulatory signals, antitumor reactivity, and scope of target tumor-associated antigens), and other treatment-related factors (such as lymphodepleting chemotherapy and postinfusion administration of interleukin-2).<\/jats:p>","DOI":"10.1136\/jitc-2023-008640","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:40:29Z","timestamp":1710376829000},"page":"e008640","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":61,"title":["Biomarkers for response to TIL therapy: a comprehensive review"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04611126","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6356-2551","authenticated-orcid":false,"given":"V\u00edctor","family":"Albarr\u00e1n Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"},{"name":"Ram\u00f3n y Cajal University Hospital, Department of Medical Oncology, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7200-0155","authenticated-orcid":false,"given":"Pablo","family":"Ballest\u00edn Mart\u00ednez","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"},{"name":"Cl\u00ednico San Carlos University Hospital, Department of Medical Oncology, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Stoltenborg Granh\u00f8j","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4402-9281","authenticated-orcid":false,"given":"Troels Holz","family":"Borch","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-9752","authenticated-orcid":false,"given":"Marco","family":"Donia","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Marie Svane","sequence":"additional","affiliation":[{"name":"National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,3,13]]},"reference":[{"key":"2025100312401474000_12.3.e008640.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01353-6"},{"key":"2025100312401474000_12.3.e008640.2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/14712598.2022.2064711","article-title":"Tumor-infiltrating lymphocytes for adoptive cell therapy: recent advances, challenges, and future directions","volume":"22","author":"Granh\u00f8j","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2025100312401474000_12.3.e008640.3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/immuno1030012","article-title":"ACT up TIL now: the evolution of tumor-infiltrating lymphocytes in adoptive cell therapy for the treatment of solid tumors","volume":"1","author":"Hulen","year":"2021","journal-title":"Immuno"},{"key":"2025100312401474000_12.3.e008640.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527"},{"key":"2025100312401474000_12.3.e008640.5","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.15.1159"},{"key":"2025100312401474000_12.3.e008640.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.00.240"},{"key":"2025100312401474000_12.3.e008640.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116"},{"key":"2025100312401474000_12.3.e008640.8","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-10-169","article-title":"Adoptive cell therapy with Autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic Melanoma patients","volume":"10","author":"Ellebaek","year":"2012","journal-title":"J Transl Med"},{"key":"2025100312401474000_12.3.e008640.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1879"},{"key":"2025100312401474000_12.3.e008640.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.7220"},{"key":"2025100312401474000_12.3.e008640.11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612"},{"key":"2025100312401474000_12.3.e008640.12","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant Interleukin-2 in advanced cutaneous Melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100312401474000_12.3.e008640.13","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or Ipilimumab in advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"2025100312401474000_12.3.e008640.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30251-6"},{"key":"2025100312401474000_12.3.e008640.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y"},{"key":"2025100312401474000_12.3.e008640.16","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.458"},{"issue":"15_suppl","key":"2025100312401474000_12.3.e008640.17","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2019.37.15_suppl.2538","article-title":"Safety and efficacy of adoptive cell transfer using Autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent Cervical carcinoma","volume":"37","author":"Jazaeri","year":"2019","journal-title":"JCO"},{"key":"2025100312401474000_12.3.e008640.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2722"},{"key":"2025100312401474000_12.3.e008640.19","doi-asserted-by":"crossref","unstructured":"Jimeno A , Papa S , Haigentz M , et al . 353\u2005Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC. Internet. 35th Anniversary Annual Meeting (SITC 2020); BMJ Publishing Group Ltd, November 2020:A215\u20136. doi:10.1136\/jitc-2020-SITC2020.0353","DOI":"10.1136\/jitc-2020-SITC2020.0353"},{"key":"2025100312401474000_12.3.e008640.20","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.21.02170","article-title":"Breast cancers are Immunogenic: immunologic analyses and a phase II pilot clinical trial using Mutation-reactive Autologous lymphocytes","volume":"40","author":"Zacharakis","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025100312401474000_12.3.e008640.21","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/7890985","article-title":"Retrospective analysis of adoptive TIL therapy plus anti-Pd1 therapy in patients with chemotherapy-resistant metastatic Osteosarcoma","volume":"2020","author":"Zhou","year":"2020","journal-title":"J Immunol Res"},{"key":"2025100312401474000_12.3.e008640.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609279"},{"key":"2025100312401474000_12.3.e008640.23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1251102"},{"key":"2025100312401474000_12.3.e008640.24","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1158\/1078-0432.CCR-22-2428","article-title":"TIL therapy: facts and hopes","volume":"29","author":"Monberg","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025100312401474000_12.3.e008640.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406498"},{"key":"2025100312401474000_12.3.e008640.26","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor Genomic biomarkers for PD-1 Checkpoint blockade-based Immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2025100312401474000_12.3.e008640.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444."},{"key":"2025100312401474000_12.3.e008640.28","doi-asserted-by":"crossref","unstructured":"Lauss M , Donia M , Harbst K , et al . Mutational and putative Neoantigen load predict clinical benefit of adoptive T cell therapy in Melanoma. Nat Commun 2017;8. doi:10.1038\/s41467-017-01460-0","DOI":"10.1038\/s41467-017-01460-0"},{"key":"2025100312401474000_12.3.e008640.29","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","article-title":"Neoantigen identification and response to adoptive cell transfer in anti-PD-1 Na\u00efve and experienced patients with metastatic Melanoma","volume":"28","author":"Levi","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"2025100312401474000_12.3.e008640.30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002703","article-title":"Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with Checkpoint inhibitor-resistant metastatic Melanoma","volume":"9","author":"Borch","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100312401474000_12.3.e008640.31","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/1078-0432.CCR-21-1060","article-title":"Genomic correlates of outcome in tumor-infiltrating lymphocyte therapy for metastatic Melanoma","volume":"28","author":"Creasy","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100312401474000_12.3.e008640.32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3649"},{"key":"2025100312401474000_12.3.e008640.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0380"},{"key":"2025100312401474000_12.3.e008640.34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of Lifileucel, a one-time Autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced Melanoma after progression on immune Checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100312401474000_12.3.e008640.35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1171"},{"key":"2025100312401474000_12.3.e008640.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.044"},{"key":"2025100312401474000_12.3.e008640.37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3655"},{"key":"2025100312401474000_12.3.e008640.38","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0501"},{"key":"2025100312401474000_12.3.e008640.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.02.024"},{"key":"2025100312401474000_12.3.e008640.40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/jitc-2021-003499","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes supported by Checkpoint inhibition across multiple solid cancer types","volume":"9","author":"Kverneland","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100312401474000_12.3.e008640.41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000668","article-title":"Future role for adoptive T-cell therapy in Checkpoint inhibitor-resistant metastatic Melanoma","volume":"8","author":"Borch","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100312401474000_12.3.e008640.42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081624","article-title":"Serum S100B, lactate dehydrogenase and brain metastasis are Prognostic factors in patients with distant Melanoma metastasis and systemic therapy","volume":"8","author":"Weide","year":"2013","journal-title":"PLoS One"},{"key":"2025100312401474000_12.3.e008640.43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/CJI.0000000000000223","article-title":"Outcomes of adoptive cell transfer with tumor-infiltrating lymphocytes for metastatic Melanoma patients with and without brain metastases","volume":"41","author":"Mehta","year":"2018","journal-title":"J Immunother"},{"key":"2025100312401474000_12.3.e008640.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.5449"},{"key":"2025100312401474000_12.3.e008640.45","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00262-019-02307-x","article-title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic Melanoma with Autologous tumor-infiltrating lymphocytes and low-dose Interleukin-2","volume":"68","author":"Nguyen","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025100312401474000_12.3.e008640.46","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0041"},{"key":"2025100312401474000_12.3.e008640.47","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/CJI.0b013e318209c94c","article-title":"\u201cEstablishment and large-scale expansion of minimally cultured \u201cyoung\u201d tumor infiltrating lymphocytes for adoptive transfer therapy\u201d","volume":"34","author":"Itzhaki","year":"2011","journal-title":"J Immunother"},{"key":"2025100312401474000_12.3.e008640.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1507"},{"key":"2025100312401474000_12.3.e008640.49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/PPO.0000000000000608","article-title":"Surgical considerations for tumor tissue procurement to obtain tumor-infiltrating lymphocytes for adoptive cell therapy","volume":"28","author":"Mullinax","year":"2022","journal-title":"Cancer J"},{"key":"2025100312401474000_12.3.e008640.50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1245\/s10434-017-6266-8","article-title":"Metastasectomy for tumor-infiltrating lymphocytes: an emerging operative indication in surgical oncology","volume":"25","author":"Crompton","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"2025100312401474000_12.3.e008640.51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.13.932"},{"key":"2025100312401474000_12.3.e008640.52","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1200\/JCO.1994.12.7.1475","article-title":"In vitro predictors of therapeutic response in Melanoma patients receiving tumor-infiltrating lymphocytes and Interleukin-2","volume":"12","author":"Schwartzentruber","year":"1994","journal-title":"JCO"},{"key":"2025100312401474000_12.3.e008640.53","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31818403d5"},{"key":"2025100312401474000_12.3.e008640.54","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.10.7046"},{"key":"2025100312401474000_12.3.e008640.55","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000211321.07654.b8"},{"key":"2025100312401474000_12.3.e008640.56","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3083.2011.02640.x"},{"key":"2025100312401474000_12.3.e008640.57","doi-asserted-by":"publisher","DOI":"10.1038\/nri1842"},{"key":"2025100312401474000_12.3.e008640.58","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181b88ffc"},{"key":"2025100312401474000_12.3.e008640.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2004.12.003"},{"key":"2025100312401474000_12.3.e008640.60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20050732"},{"key":"2025100312401474000_12.3.e008640.61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1177"},{"key":"2025100312401474000_12.3.e008640.62","doi-asserted-by":"crossref","first-page":"100113","DOI":"10.1016\/j.iotech.2022.100113","article-title":"8p Phenotypic characterization of infused tumor-infiltrating lymphocytes (TIL) correlates with response to adoptive cellular therapy (ACT)","volume":"16","author":"Stoltenborg Granh\u00f8j","year":"2022","journal-title":"Immuno-Oncology and Technology"},{"key":"2025100312401474000_12.3.e008640.63","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1101244"},{"key":"2025100312401474000_12.3.e008640.64","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","article-title":"Cd8+ T cell immunity against a tumor\/self-antigen is augmented by Cd4+ T helper cells and hindered by naturally occurring T regulatory cells","volume":"174","author":"Antony","year":"2005","journal-title":"The Journal of Immunology"},{"key":"2025100312401474000_12.3.e008640.65","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007288","article-title":"Neoantigen-specific Cd4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic Melanoma patients","volume":"11","author":"Hall","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025100312401474000_12.3.e008640.66","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31819c8bda"},{"key":"2025100312401474000_12.3.e008640.67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.6441"},{"key":"2025100312401474000_12.3.e008640.68","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200205000-00007"},{"key":"2025100312401474000_12.3.e008640.69","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200107000-00012"},{"key":"2025100312401474000_12.3.e008640.70","first-page":"4S1","article-title":"Characterization of the Transcriptomic and T-cell receptor (TCR) Clonal heterogeneity of tumor-infiltrating lymphocyte (TIL) therapy infusion products by single-cell sequencing and correlative analyses with clinical efficacy in patients with advanced cutaneous Melanoma","volume":"30","author":"Yuan","year":"2022","journal-title":"Mol Ther"},{"key":"2025100312401474000_12.3.e008640.71","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150535","article-title":"Neoantigen-reactive Cd8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in Melanoma","volume":"132","author":"Kristensen","year":"2022","journal-title":"J Clin Invest"},{"key":"2025100312401474000_12.3.e008640.72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.06.020"},{"key":"2025100312401474000_12.3.e008640.73","doi-asserted-by":"publisher","DOI":"10.1038\/nri2781"},{"key":"2025100312401474000_12.3.e008640.74","doi-asserted-by":"crossref","first-page":"619954","DOI":"10.3389\/fimmu.2020.619954","article-title":"The dual roles of human \u0393\u03b4 T cells: anti-tumor or tumor-promoting","volume":"11","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"2025100312401474000_12.3.e008640.75","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1186\/2051-1426-2-S3-P243","article-title":"Predictive immune biomarker signatures in the tumor Microenvironment of Melanoma metastases associated with tumor-infiltrating lymphocyte (TIL) therapy","volume":"2","author":"Chen","year":"2014","journal-title":"J Immunotherapy Cancer"},{"key":"2025100312401474000_12.3.e008640.76","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41571-022-00689-z","article-title":"Clinical implications of T cell exhaustion for cancer Immunotherapy","volume":"19","author":"Chow","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100312401474000_12.3.e008640.77","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0962"},{"key":"2025100312401474000_12.3.e008640.78","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41416-019-0384-y","article-title":"Tumour-reactive T cell Subsets in the Microenvironment of ovarian cancer","volume":"120","author":"Westergaard","year":"2019","journal-title":"Br J Cancer"},{"key":"2025100312401474000_12.3.e008640.79","doi-asserted-by":"publisher","DOI":"10.1172\/JCI73639"},{"key":"2025100312401474000_12.3.e008640.80","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1014246","article-title":"BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in Melanoma with enhanced survival properties","volume":"4","author":"Haymaker","year":"2015","journal-title":"OncoImmunology"},{"key":"2025100312401474000_12.3.e008640.81","article-title":"Foxp3 Associates with enhancer-promoter loops to regulate Treg-specific gene expression","volume":"7","author":"Ramirez","year":"2022","journal-title":"Sci Immunol"},{"key":"2025100312401474000_12.3.e008640.82","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.cmet.2016.12.018","article-title":"Foxp3 Reprograms T cell metabolism to function in low-glucose, high-lactate environments","volume":"25","author":"Angelin","year":"2017","journal-title":"Cell Metabolism"},{"key":"2025100312401474000_12.3.e008640.83","doi-asserted-by":"publisher","DOI":"10.1038\/nri2785"},{"key":"2025100312401474000_12.3.e008640.84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-163048"},{"key":"2025100312401474000_12.3.e008640.85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386482"},{"key":"2025100312401474000_12.3.e008640.86","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318209e7ec"},{"key":"2025100312401474000_12.3.e008640.87","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0945"},{"key":"2025100312401474000_12.3.e008640.88","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb9847"},{"key":"2025100312401474000_12.3.e008640.89","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1182-4"},{"key":"2025100312401474000_12.3.e008640.90","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-3205"},{"key":"2025100312401474000_12.3.e008640.91","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose Interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"},{"key":"2025100312401474000_12.3.e008640.92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"2025100312401474000_12.3.e008640.93","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-020-00538-5","article-title":"IL-9 and IL-9-producing cells in tumor immunity","volume":"18","author":"Wan","year":"2020","journal-title":"Cell Commun Signal"},{"key":"2025100312401474000_12.3.e008640.94","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113344","article-title":"Qualitative analysis of tumor-infiltrating lymphocytes across human tumor types reveals a higher proportion of bystander Cd8+ T cells in non-Melanoma cancers compared to Melanoma","volume":"12","author":"Gokuldass","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025100312401474000_12.3.e008640.95","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.18632\/oncotarget.27604","article-title":"Adoptive cell therapy in combination with Checkpoint inhibitors in ovarian cancer","volume":"11","author":"Kverneland","year":"2020","journal-title":"Oncotarget"},{"key":"2025100312401474000_12.3.e008640.96","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.omto.2022.01.004","article-title":"Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy","volume":"24","author":"Chamberlain","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"2025100312401474000_12.3.e008640.97","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181fb045d"},{"key":"2025100312401474000_12.3.e008640.98","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2482"},{"key":"2025100312401474000_12.3.e008640.99","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1006619"},{"key":"2025100312401474000_12.3.e008640.100","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.1416","article-title":"1032Tip A phase I, first-in-human, study of TILT-123, a tumor-selective Oncolytic adenovirus Encoding Tnfa and IL-2, in participants with advanced Melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes","volume":"32","author":"Svane","year":"2021","journal-title":"Annals of Oncology"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-008640","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:40:29Z","timestamp":1759520429000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-008640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":100,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,13]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/jitc-2023-008640"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-008640","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}